AU2022273023A1 - Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine - Google Patents

Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine Download PDF

Info

Publication number
AU2022273023A1
AU2022273023A1 AU2022273023A AU2022273023A AU2022273023A1 AU 2022273023 A1 AU2022273023 A1 AU 2022273023A1 AU 2022273023 A AU2022273023 A AU 2022273023A AU 2022273023 A AU2022273023 A AU 2022273023A AU 2022273023 A1 AU2022273023 A1 AU 2022273023A1
Authority
AU
Australia
Prior art keywords
count
nadir
baseline
absolute neutrophil
human subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022273023A
Other languages
English (en)
Inventor
William B. AINSWORTH
John Hayslip
Steve H. KYE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of AU2022273023A1 publication Critical patent/AU2022273023A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dermatology (AREA)
AU2022273023A 2021-05-11 2022-05-10 Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine Abandoned AU2022273023A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201749P 2021-05-11 2021-05-11
US63/201,749 2021-05-11
PCT/US2022/028429 WO2022240786A1 (en) 2021-05-11 2022-05-10 Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine

Publications (1)

Publication Number Publication Date
AU2022273023A1 true AU2022273023A1 (en) 2023-11-23

Family

ID=84028499

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022273023A Abandoned AU2022273023A1 (en) 2021-05-11 2022-05-10 Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine

Country Status (11)

Country Link
US (1) US20220378811A1 (https=)
EP (1) EP4337183A4 (https=)
JP (1) JP2024517318A (https=)
KR (1) KR20240006659A (https=)
CN (1) CN117642161A (https=)
AU (1) AU2022273023A1 (https=)
BR (1) BR112023023677A2 (https=)
CA (1) CA3219760A1 (https=)
IL (1) IL308321A (https=)
MX (1) MX2023013364A (https=)
WO (1) WO2022240786A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052346B2 (en) * 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
KR20220004669A (ko) * 2019-04-29 2022-01-11 이뮤노젠 아이엔씨 항-cd123 면역접합체를 포함하는 치료적 조합물
JP2022537551A (ja) * 2019-06-20 2022-08-26 セルジーン・クオンティセル・リサーチ・インコーポレイテッド ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
WO2021037933A1 (en) * 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer

Also Published As

Publication number Publication date
MX2023013364A (es) 2023-11-27
US20220378811A1 (en) 2022-12-01
EP4337183A4 (en) 2025-04-23
KR20240006659A (ko) 2024-01-15
WO2022240786A1 (en) 2022-11-17
EP4337183A1 (en) 2024-03-20
JP2024517318A (ja) 2024-04-19
IL308321A (en) 2024-01-01
CA3219760A1 (en) 2022-11-17
CN117642161A (zh) 2024-03-01
BR112023023677A2 (pt) 2024-02-20

Similar Documents

Publication Publication Date Title
McKeage et al. Basiliximab: a review of its use as induction therapy in renal transplantation
WO2006119395A2 (en) Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
US20220370481A1 (en) Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine
AU2022273023A1 (en) Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
TW202200202A (zh) 非耗竭性抗ｃｄ６單株抗體於治療細胞激素風暴之用途
Bonaros et al. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation
Kromer et al. Response of recalcitrant generalized morphea to intravenous immunoglobulins (IVIg): three cases and a review of the literature
Goland et al. Induction therapy with thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates
Lutfi et al. The emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas
El Cheikh et al. Risk-adapted approach to HLA-matched sibling hematopoietic cell allografting: impact of adjusting conditioning intensity and integrating post-transplant therapeutic interventions
Rodríguez Management of the adverse effects of lenalidomide in multiple myeloma
WO2025045766A1 (en) Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same
HK40106739A (zh) 与阿扎胞苷联合用於治疗骨髓增生异常综合征的维奈托克给药方案
HK40106881A (zh) 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案
WO2025223394A1 (en) Combination therapy for classic hodgkin's lymphoma
WO2025040080A1 (en) Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy
WO2025122961A1 (en) Methods for treating neutropenia
WO2025209478A1 (en) Methods of treatment warm autoimmune hemolytic anemia using sovleplenib
CN121358495A (zh) 用于治疗系统性硬化症的免疫球蛋白制剂
WO2026091825A1 (zh) 抗cd3/cd20双特异性抗体在制备用于治疗cd20阳性b-nhl的药物中的用途
TW202423968A (zh) Ｃｄ３８結合融合蛋白組合療法
Procopio et al. Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors
Schmitt et al. CLINICAL NEPHROLOGY-EPIDEMIOLOGY-CLINICAL TRIALS Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): An open study in 15 patients.
Graham et al. 01 Cytokine Release Syndrome